TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06103721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection [Precedex]
Description: Dexmedetomidine will be diluted in 20 ml of Normal Saline to produce a concentration of 20 mcg/ml. Then it will be taken from the dilution at a dose of 1.0 mcg/kg and that will be added in 2-3 ml of Normal Saline to make it a final volume of 10ml. The resultant mixture will be used to nebulize the patients for 5 minutes, 15 minutes prior to induction of General Anesthesia. Then general anesthesia will be induced with 1mg of Midazolam, 2mg/kg of Propofol, 0.5 mg/kg of Atracurium. Prior to endotracheal tube placement, airway will be managed with bag mask ventilation for 3 minutes. Vitals will be measured pre-nebulization, pre-induction, at 1 minute intervals during bag mask ventilation and immediately after placement of endotracheal tube.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Patients in the placebo group will be nebulized with 10 ml of Normal Saline, 15 minutes prior to induction of general anesthesia. Then general anesthesia will be induced with 1mg of Midazolam, 2mg/kg of Propofol, 0.5 mg/kg of Atracurium. Prior to endotracheal tube placement, airway will be managed with bag mask ventilation for 3 minutes. Vitals will be measured pre-nebulization, pre-induction, at 1 minute intervals during bag mask ventilation and immediately after placement of endotracheal tube.
Study: NCT04966936

Intervention type: OTHER
Intervention: questionnaires for clinical assessments
Description: Amputee Mobility Predictor, Locomotor Capacity Index, visual analog scale (VAS)

Intervention type: OTHER
Intervention: questionnaires for clinical assessments
Description: Amputee Mobility Predictor, Locomotor Capacity Index, visual analog scale (VAS)

Intervention type: OTHER
Intervention: questionnaires for clinical assessments
Description: Amputee Mobility Predictor, Locomotor Capacity Index, visual analog scale (VAS)

Intervention type: OTHER
Intervention: 2 minute walking test
Description: the individual is asked to walk in his natural course within 2 minutes on a track whose distance is measured beforehand, and at the end of two minutes, the distance he walks will be recorded in meters (m).

Intervention type: OTHER
Intervention: 2 minute walking test
Description: the individual is asked to walk in his natural course within 2 minutes on a track whose distance is measured beforehand, and at the end of two minutes, the distance he walks will be recorded in meters (m).

Intervention type: OTHER
Intervention: 2 minute walking test
Description: the individual is asked to walk in his natural course within 2 minutes on a track whose distance is measured beforehand, and at the end of two minutes, the distance he walks will be recorded in meters (m).

Intervention type: OTHER
Intervention: The gait analysis at the motion analysis laboratory.
Description: Temporo-spatial parameters (gait speed (m/s), cadence (step/s), other foot contact (%), double support time (second), single support time (second), stance phase time (sec), swing phase time (sec), stride length (meters)) and kinematic parameters (hip, knee, ankle joint angles (frontal, sagittal, transverse plane), maximum knee flexion angles in the stance and swing phase, velocity-dependent maximum knee flexion angles in the swing phase, knee flexion moments will be compared

Intervention type: OTHER
Intervention: The gait analysis at the motion analysis laboratory.
Description: Temporo-spatial parameters (gait speed (m/s), cadence (step/s), other foot contact (%), double support time (second), single support time (second), stance phase time (sec), swing phase time (sec), stride length (meters)) and kinematic parameters (hip, knee, ankle joint angles (frontal, sagittal, transverse plane), maximum knee flexion angles in the stance and swing phase, velocity-dependent maximum knee flexion angles in the swing phase, knee flexion moments will be compared

Intervention type: OTHER
Intervention: The gait analysis at the motion analysis laboratory.
Description: Temporo-spatial parameters (gait speed (m/s), cadence (step/s), other foot contact (%), double support time (second), single support time (second), stance phase time (sec), swing phase time (sec), stride length (meters)) and kinematic parameters (hip, knee, ankle joint angles (frontal, sagittal, transverse plane), maximum knee flexion angles in the stance and swing phase, velocity-dependent maximum knee flexion angles in the swing phase, knee flexion moments will be compared
Study: NCT05562492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CamAPS FX
Description: The automated closed loop system (CamAPS FX) will consist of:~YpsoPump insulin pump (Ypsomed, Burgdorf, Switzerland) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor Cloud upload system to review CGM/insulin data.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard insulin therapy with CGM
Description: Usual insulin therapy and study CGM.
Study: NCT06502379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8965
Description: AZD8965 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8965
Description: AZD8965 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8965
Description: AZD8965 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8965
Description: AZD8965 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8965
Description: AZD8965 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8965
Description: AZD8965 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8965
Description: AZD8965 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8965
Description: AZD8965 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8965
Description: AZD8965 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8965
Description: AZD8965 will be administered orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally.
Study: NCT05787379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concordant Care Training
Description: Concordant Care training has four components. 1. Clinicians will complete \~3 hours of online, asynchronous training that will teach them practices including validate Veterans' experiences with Long-COVID, develop shared understanding with patients about Long-COVID, and develop patient-centered action plans. Clinicians will be provided with handouts, case examples, video demonstrations, and practice exercises to help them integrate these practices into care. 2. Tele-mentoring groups will be offered \~bi-weekly and be open to all clinician participant in the Concordant Training arm. Content will include review of specific cases, didactics on specific Concordant Care practices, role-play exercises, and review of session recordings. At least two sessions are required. 3. Clinician Pocket Card that serves as a reminder of the Concordant Care process. 4. An electronic prompt will be sent to enrolled Veterans encouraging them to speak with their clinician about their Long-COVID concerns.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Packet Training
Description: Clinicians randomized to the control arm will receive a comprehensive information packet with the latest understanding of Long-COVID. Clinicians will also be provided a packet directing them to relevant VA trainings for Long-COVID. Whole Health trainings which focus on wholistic integrated approaches to care will be highlighted. Whole Health is important for all Veterans, and it is thought to be particularly relevant for poorly understood conditions that don't easily fit in traditional medical model.
Study: NCT06560970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPPEhR Intervention
Description: Participants will receive access to the COPPEhR system which will provide social support and engagement among older adults diagnosed with HIV.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Device-only Control Condition
Description: Participants will have access to a device only without the COPPEhR system.
Study: NCT05794191

Intervention type: BIOLOGICAL
Intervention: Vaccine Administration
Description: PCV13 administration
Study: NCT05398484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 25 mgs
Description: One capsule containing 25mg of psilocybin will be administered with water orally. The appearance of psilocybin is Size 2 HPMC opaque.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niacin 100mg
Description: One capsule contains 100mg of niacin will be administered with water orally. The appearance of the active placebo is Size 2 HPMC opaque.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: The manualized psychotherapy platform will consist of 6 hours of preparatory psychotherapy (prior to the single medication session) and 8 hours of integration psychotherapy following the dosing session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: The manualized psychotherapy platform will consist of 6 hours of preparatory psychotherapy (prior to the single medication session) and 8 hours of integration psychotherapy following the dosing session.
Study: NCT05748405

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEF0217
Description: Tablets of 100 mcg AEF0217
Study: NCT06216691

Intervention type: OTHER
Group type: OTHER
Intervention: Coach-guided smartphone delivered CBT program.
Description: All eligible participants will be enrolled in an 8-week coach-guided smartphone delivered CBT program. The full duration of the program, with follow-up interview, will be 9 weeks.
Study: NCT06092879

Intervention type: OTHER
Intervention: Asciminib
Description: There is no treatment allocation. Patients administered Asciminib by prescription will be enrolled
Study: NCT04971395

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of 2 or 4 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XTMAB-16 2 mg/kg
Description: Single dose of 2 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XTMAB-16 4mg/kg
Description: Single dose of 4 mg/kg
Study: NCT06106945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0305
Description: AZD0305
Study: NCT05868525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 325Mg Tab, Aspirin 81Mg Tab
Description: Patients will be administrated daily oral Aspirin 81 mg or oral Aspirin 325 mg according to their assigned group after randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 325Mg Tab, Aspirin 81Mg Tab
Description: Patients will be administrated daily oral Aspirin 81 mg or oral Aspirin 325 mg according to their assigned group after randomization.
Study: NCT05648773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messaging
Description: Booster reminder message

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messaging
Description: Booster reminder message

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Financial Incentive for getting boosted within 2-weeks of the message
Study: NCT05093777

Intervention type: OTHER
Group type: OTHER
Intervention: Program Intensified Habilitation
Description: The program is based on a holistic and family-centered concept, which acknowledges parents as experts on their child's abilities and needs. The program involves both parents and local professionals, and includes goal setting and goal-directed treatment targeted to the needs of the individual child. The program lasts for about one year and contains three in-patient group sessions over 2 weeks. In between the children are receiving individualized home training programs at home and in pre-school/kindergarten. The children train on a daily basis, both during the inpatient sessions and in the home setting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Program Intensified Habilitation
Description: The program is based on a holistic and family-centered concept, which acknowledges parents as experts on their child's abilities and needs. The program involves both parents and local professionals, and includes goal setting and goal-directed treatment targeted to the needs of the individual child. The program lasts for about one year and contains three in-patient group sessions over 2 weeks. In between the children are receiving individualized home training programs at home and in pre-school/kindergarten. The children train on a daily basis, both during the inpatient sessions and in the home setting.

Intervention type: OTHER
Group type: OTHER
Intervention: Habilitation as usual
Description: When the participants are not joining the study year containing the intervention program, they will be offered habilitation services as usual administered by the primary health care services in the local community.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Habilitation as usual
Description: When the participants are not joining the study year containing the intervention program, they will be offered habilitation services as usual administered by the primary health care services in the local community.
Study: NCT05648773

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment as usual; no additional message and no incentive.
Study: NCT04491825

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin suction blistering and skin biopsies
Description: Skin suction blistering and skin biopsies will be used for the identification of potential proteomic biomarkers that can distinguish MF from eczema, psoriasis and healthy control skin.

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin suction blistering and skin biopsies
Description: Skin suction blistering and skin biopsies will be used for the identification of potential proteomic biomarkers that can distinguish MF from eczema, psoriasis and healthy control skin.
Study: NCT04701047

Intervention type: DEVICE
Intervention: vaginal pessary
Description: insertion and follow up of a vaginal pessary
Study: NCT06304987

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Long-course chemoradiation and PD-1 inhibitor, with PCSK9 inhibitor
Description: In long-course chemoradiotherapy (CRT) + PD-1 inhibitor for LARC patients, the experimental group used concurrent PCSK9 inhibitor, and the active comparison group did not use PCSK9 inhibitor.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Long-course chemoradiation and PD-1 inhibitor, without PCSK9 inhibitor
Description: In long-course chemoradiotherapy (CRT) + PD-1 inhibitor for LARC patients, the experimental group used concurrent PCSK9 inhibitor, and the active comparison group did not use PCSK9 inhibitor.
Study: NCT05071599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twin Arch Brackets
Description: Twin Arch Brackets characterized by double horizontal slots which make it capable to accept two arch wire at the same time which in turn can achieve a better control over orthodontic tooth movement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twin Arch Brackets
Description: Twin Arch Brackets characterized by double horizontal slots which make it capable to accept two arch wire at the same time which in turn can achieve a better control over orthodontic tooth movement
Study: NCT04701047

Intervention type: PROCEDURE
Intervention: Vaginal prolapse surgery
Description: surgery and follow up after vaginal prolapse surgery
Study: NCT05694780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep intervention
Description: Standard obstetric care plus the sleep intervention which is a 8-week program based on sleep hygiene education and cognitive-behavioral training.
Study: NCT05823233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold application+Deep friction+Home exercise+Eccentric stretching
Description: In our study, deep friction massage will be performed by the researcher with the tip of the thumb, maintaining the pressure for 3-5 minutes in the posterior direction to the tenoosseous junction. The application will be performed 3 times a week for a total of 12 sessions for 4 weeks. After the deep friction massage, cold application will be made for 15 minutes. Simultaneously with the electrical stimulation of the affected arm, the patient will be asked to stretch for 5 seconds and rest for 5 seconds, and doing this 15 times will be considered 1 set. After 1 minute of rest, he will be asked to do this practice for 2 more sets, so 3 sets of 15 repetitions will be completed in total. A total of 12 sessions will be applied 3 days a week for 4 weeks. In our study, a home exercise program consisting of passive stretching and strengthening (concentric and eccentric) exercises will be applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold application+Deep friction+Home exercise
Description: In our study, deep friction massage will be performed by the researcher with the tip of the thumb, maintaining the pressure for 3-5 minutes in the posterior direction to the tenoosseous junction. The application will be performed 3 times a week for a total of 12 sessions for 4 weeks. After the deep friction massage, cold application will be made for 15 minutes. In our study, a home exercise program consisting of passive stretching and strengthening (concentric and eccentric) exercises will be applied.
Study: NCT04769193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adipeau face cream
Description: Adipeau face cream contains the natural actives Carthamus Tinctorius (Safflower) Seed Oil and Kaempferia Parviflora Rhizome Extract (Black Ginger).
Study: NCT04848064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Killer Cell Therapy
Description: Given via infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05776888

Intervention type: OTHER
Intervention: Ofatumumab
Description: There is no treatment allocation. For both cohorts, only patients that have received Ofatumumab treatment for at least 3 months prior to inclusion in the study will be enrolled.

Intervention type: OTHER
Intervention: Ofatumumab
Description: There is no treatment allocation. For both cohorts, only patients that have received Ofatumumab treatment for at least 3 months prior to inclusion in the study will be enrolled.
Study: NCT05994235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Mosunetuzumab will be administered in weekly dose increments (step-up dosing) during Cycle 1 and then on Day 1 of each cycle. Mosunetuzumab will be given in 28-day cycles for up to 12 cycles. Mosunetuzumab will be administered SC at the dose of 5 mg on Day 1, 45 mg on Day 8, and 45 mg on Day 15 in Cycle 1. Beginning with Cycle 2, it will be administered SC at the dose of 45 mg on Day 1. Each cycle lasts 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat Pill
Description: Oral tazemetostat will be administered by mouth twice daily at standard dosing (800 mg twice daily) beginning at the same time as mosunetuzumab initiation until disease progression, unacceptable toxicity, or consent is withdrawn. Patients will remain on tazemetostat for up to twelve 28-day cycles from initiation of mosunetuzumab.
Study: NCT05118919

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BGP-014
Description: Oral capsule containing lyophilised Lactobacillus reuteri

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study: NCT05948540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention C Daridorexant
Description: Daridorexant will be administered 50 mg once daily at least 2 hours after the last meal and within 30 minutes of going to bed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intervention C Placebo
Description: A matching placebo will be administered at 50 mg daily in the same regimen as the intervention.
Study: NCT06557265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKX019
Description: NKX019 is an investigational allogeneic CD19-Directed CAR NK

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepletion
Study: NCT06642610

Intervention type: DEVICE
Group type: OTHER
Intervention: CGM Dynamic Index (CDI)
Description: Participants will undergo one-time oral glucose tolerance test (OGTT) and a one-time use of a CGM device, which will be worn for up to 10 days.
Study: NCT05954780

Intervention type: DRUG
Intervention: Selinexor
Description: Selinexor/bortezomib/dexamethasone according to Nexpovio® SmPC